A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer
| Autor: | Leora Horn, Yu Shyr, Steven N. Wolff, Janessa Laskin, Alan Sandler, Russell F. DeVore, Zhiguo Zhao, David P. Johnson |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Pulmonary and Respiratory Medicine
Oncology Male Cancer Research medicine.medical_specialty Lung Neoplasms Nausea Phases of clinical research Neutropenia Irinotecan Carboplatin chemistry.chemical_compound Internal medicine Antineoplastic Combined Chemotherapy Protocols Medicine Humans Extensive stage Lung cancer neoplasms Neoplasm Staging Performance status business.industry Middle Aged medicine.disease Small Cell Lung Carcinoma chemistry Camptothecin Female medicine.symptom business medicine.drug |
| Zdroj: | Clinical lung cancer. 12(3) |
| ISSN: | 1938-0690 |
| Popis: | Objectives Our study set out to determine the antitumor efficacy of carboplatin and irinotecan as assessed by response rate in persons with chemotherapy-naive extensive-disease, small-cell lung cancer (ED-SCLC). Secondary objectives included progression-free survival (PFS), overall survival, and toxicity findings. Methods Patients with previously untreated ED-SCLC, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2, life expectancy ≥ 3 months, and adequate organ function were eligible. Patients were treated with carboplatin AUC 5 intravenously over 30-60 minutes on day 1, followed by CPT-11(irinotecan) 50 mg/m 2 intravenously over 30-90 minutes on days 1 and 8 every 3 weeks for 4-6 cycles at the discretion of the treating physician. Results Fifty-six patients were enrolled, and 50 patients were eligible. The median age of patients was 60.1 years. The most common toxicities were neutropenia, thrombocytopenia, nausea/vomiting, and dehydration. The overall response rate was 58%. Median PFS was 5.3 months, median overall survival was 9.7 months, and 1-year overall survival was 28.7%. Conclusions Carboplatin and irinotecan is a safe and reasonable combination for the treatment of patients with ED-SCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect